


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR CLINICAL TRIAL OF
TQB3122 “PARP1 INHIBITOR” ACCEPTED BY NMPA

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Investigational New Drug (IND) application for TQB3122 “PARP1 Inhibitor”, an innovative drug intended for the treatment of advanced malignant tumors independently developed by the Group has been accepted by the National Medical Products Administration of China (NMPA).

TQB3122 is a PARP1 inhibitor with high selectivity and blood-brain barrier penetration capacities, and can exert its antitumor effects through a dual mechanism: on the one hand, it competitively inhibits the catalytic activity of the PARP1 enzyme, while blocking the repair of any single-strand DNA breaks; on the other hand, it stabilises the DNA-PARP complex through a “trapping” mechanism, thereby hindering the progression of replication forks. Based on the principle of “synthetic lethality,” TQB3122 selectively kills tumor cells with BRCA mutations or homologous recombination defects. Studies have shown that TQB3122 is of significant efficacy in multiple tumor models and has outstanding brain tissue distribution capabilities, which make it a potential new option for the treatment of intracranial tumors.

Currently, there are no drugs with the same target approved for marketing worldwide. The Group will explore the safety and efficacy of TQB3122 in advanced solid tumors, with the potential to provide new treatment options for patients worldwide.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 11 August 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.